Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew David Hellmann, Luis G Paz-Ares, Reyes Bernabé et al. · New England Journal of Medicine · 2019
BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more. RESULTS: Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy. CONCLUSIONS: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).
Cited by 2,815 works. doi:10.1056/nejmoa1910231 Open-access PDF
Authors
- Matthew David Hellmann
- Luis G Paz-Ares
- Reyes Bernabé
- Bogdan A. Żurawski
- Sang‐We Kim
- Enric Carcereny
- Keunchil Park
- Aurelia Alexandru
- Lorena Lupinacci
- Emmanuel de la Mora Jimenez
- Hiroshi Sakai
- Alain Vergnenégre
- Solange Peters
- Konstantinos Syrigos
- Fabrice Barlési
- Martin Reck
- Hossein Borghaei
- Julie Renee Brahmer
- Kenneth John O'Byrne
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden